Fire department rallies for firefighter battling cancer
Robert Cornelius is the kind of firefighter every department wishes to have. For the last 28 years, he hasn't just worn the badge for the Frontier Volunteer Fire Company — he's lived it.
'Rob has been a huge, huge player,' said Rich Silvaroli, former chief of the Frontier Volunteer Fire Company. 'He was on many calls among this neighborhood helping our neighbors here at Frontier.'
Now, the man who has answered thousands of calls for help is facing something he can't battle on his own.
In March, Cornelius was diagnosed with stage 3 esophageal cancer. It's a disease that's tragically common among the very heroes who run toward danger.
'When you hear it from one of your own members, it hurts,' said Alan Perry, chief of the Frontier Volunteer Fire Company. 'The only thing we can do is give back to him as much as he's given back to us.'
Cornelius described the moment he found out the news.
'It was devastating just thinking about the girls and family,' said Cornelius.
Day by day with rounds of chemotherapy and hospital visits, he continues to put his family first.
'When we were younger, it was him watching us struggle,' said Aurora Cornelius, one of Rob's daughters. 'If we fell and scraped our knee, he was the one to pick us up and put a Band-Aid on it and tell us we were going to be OK. Now, we kind of have to do the same for him.'
In the Cornelius family, firefighting isn't just a duty, it's a legacy, five generations strong. It was never a question if his daughters would also become firefighters.
'Seeing my dad when I was younger, it was very inspiring,' said Faith Cornelius, Rob's daughter. 'It was pretty easy to know where I was heading.'
'It was just having the same people in your life and being able to fall back on them when something like this happens,' said Aurora Cornelius.
At Frontier, the bond is described as a brotherhood, which means standing by each other when it matters most.
'It's a big family,' said Silvaroli. 'We come together, and when one of our family members gets sick, it means a lot to us and (we) want to help out as much as we can.'
To help support Rob, the fire company is holding a benefit on July 19 from 3 p.m. until 9 p.m., with all profits going to Cornelius and his family. It will be a pasta dinner with basket raffles and the chance to give back to the man who has given so much.
Family members said the response from the community has already been immense, with fire departments near and far donating what they can.
'Watching all these people come and support him and do these things for him, it just fills your heart with gladness,' said Rochelle Earp, Rob's sister. 'Firefighters and EMS meet you at your worst possible moment, and they're not jaded, they're amazing and just keep going.'
Cornelius told WIVB News 4 that his chemotherapy has been working. He will undergo surgery on June 26.
He's urging other firefighters across New York State to get tested.
'I'm going to be around for another 20 to 30 years,' said Cornelius. 'I want to be here for my kids, watch them get married and have kids of their own.'
For tickets to the event, you can contact chief Alan Perry at 716-930-1109 or treasurer Denise Morreale at 716-622-6324.
If you'd like to make a donation in the form of a check, you can make it out to Robert Cornelius. You can drop it off, along with baskets or pasta for the dinner, at 2176 Liberty Dr.
There is also a GoFundMe family members have started to support Rob's journey, which you can find here.
Trina Catterson joined the News 4 team in 2024. She previously worked at WETM-TV in Elmira, a sister station of WIVB. See more of her work here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
The Wistar Institute Receives $17 Million NIH Grant for Personalized HIV Cure Research
Philadelphia-led consortium is selected to tailor HIV curative strategies to participant Philadelphia, PA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute announces the National Institutes of Health (NIH) granted a five-year, $17 million research award to launch iCure Consortium to develop individualized 'cure regimens' for HIV. The Wistar-led, iCure Consortium's objective is to advance strategies to cure HIV through tailored personalized medicine. 'Today 38 million people still live with HIV worldwide, and 1.3 million contract the virus each year,' said Luis J. Montaner, D.V.M., iCure principal investigator, executive vice president of The Wistar Institute and director of Wistar's HIV Cure and Viral Diseases Center. 'For the first time, this grant brings our best team together working towards a cure tailored to each participant by pairing the latest in neutralizing antibody and cell-therapy breakthroughs against the unique, person-specific features of HIV.' iCure Consortium will test a six-part, individually-tailored therapy designed to wipe out the persistent viral reservoir that remains after antiretroviral therapy in an effort to deliver durable, drug-free remission. The project combines six advanced tactics—neutralizing antibodies, mRNA therapy, viral binders, engineered CAR-T and 'Natural Killer' (NK) cells, and precision latency 'wake-up' drugs—all designed against each patient's unique virus. 'Ending HIV demands more than management—it demands eradication,' said Drew Weissman, M.D., Ph.D., iCure co‑principal investigator, 2023 Nobel Laureate and Roberts Family Professor in Vaccine Research at the Perelman School of Medicine at the University of Pennsylvania. 'This project now allows us to apply our breakthroughs in RNA therapy as part of a cure-directed strategy.' How iCure Works• Wake the latent virus• Map and target unique weak spots with tailored antibodies• Destroy infected cells using 'super‑charged' CAR‑T and NK cells• Enhance clearance and block relapse with bispecific binders In the first step, researchers reactivate the virus in a sample of the participant's blood and identify mutations that the participant has not yet developed antibodies against. They then develop a tailored antibody therapy cocktail specifically designed against these specific mutations. In the next stage, researchers focus on preventing HIV from returning. To do this, they develop person-specific antibodies or small molecule binders that can act as 'homing devices' — beacons that can lead immune cells to the latent virus. Then they genetically modify CAR-T cells and NK cells (immune cells that destroy viruses) to express or use these homing devices to better clear infected cells. Finally, researchers further enhance NK cells. First, they develop stronger and more durable cells, called adaptive NK cells, by supercharging their virus-killing ability. Then, they deploy small-molecule drugs called bispecifics, which bind NK cells to the infected cells they are targeting. "iCure takes full advantage of the advances made in understanding how and where HIV hides from the immune system," said Montaner. "We've built on our knowledge and can use that information to identify a first of its kind targeting to a person's unique HIV features." iCure furthers the research groundwork laid by the BEAT-HIV Martin Delaney Collaboratory ( a Philadelphia-based consortium of more than 95 leading HIV researchers co-led by Dr. Montaner. Montaner called the NIH grant a 'once in a lifetime opportunity' that reflects Wistar's track record as a scientific leader in the effort to develop an HIV cure, as well as its grassroots support and collaboration with the HIV community. 'By the end of this study we hope to have a process by which to identify the virus that we need to go after in each person and have a basis to design clinical trials choosing the best of these strategies to move forward,' said Montaner. Other institutions participating in this study include Johns Hopkins Medicine and iCure co-principal investigator Robert Siliciano, M.D., Ph.D., the University of Pennsylvania, Philadelphia FIGHT, the Ragon Institute at Harvard University, George Washington University, Duke University, and Massachusetts Institute of Technology. The iCure program is funded by the National Institute of Allergy and Infectious Diseases, part of NIH, under award number UM1AI191272. ### The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@ in to access your portfolio
Gizmodo
19 minutes ago
- Gizmodo
Researchers Find Strange Link Between Marathon Running and Cancer
Some of the most physically fit people in the world may have a unique health risk. New research uncovers a possible link between marathon running and colorectal cancer. Oncologists at the Inova Schar Cancer Institute in Virginia conducted the study, which examined the colons of relatively young people who had run several long-distance races. They found these runners had a much higher rate of having potentially dangerous adenomas (a type of polyp) than would be expected for their age. Though the findings are preliminary and require more confirmation, they may point to a real connection between colorectal cancer and extreme physical activity. 'It tells us there's a signal here,' David Lieberman, a gastroenterologist and professor emeritus at Oregon Health and Science University not affiliated with the study, told the New York Times Tuesday. 'We wouldn't have expected these rates of high-risk adenomas, which are cancer precursor lesions, in an age group like this.' Lead researcher Timothy Cannon was inspired to perform the study after he treated three young patients with colorectal cancer, all of whom had run ultramarathons (defined as any race longer than 26.2 miles). Not only were his patients fit, but they were also much younger than the typical case, the oldest being 40. In 2022, Cannon and his colleagues began recruiting endurance athletes for their prospective study. The volunteers had all run at least two ultramarathons or five regular marathons; they also had no family history of colorectal cancer or other apparent risk factors. All told, 100 athletes between the ages of 35 and 50 took part and were given colonoscopies. People Who Are More Flexible Tend to Live Longer, Study Finds The researchers went looking for advanced adenomas in the colons of their volunteers, relatively large or otherwise unusual polyps. Though these growths are themselves benign, they have a higher risk of turning cancerous than other polyps. Then they compared the rate of finding these polyps in their athletes to historical trends. About 1.2% of people in their 40s at average risk for colorectal cancer would be expected to have advanced adenomas, according to the researchers. By sharp contrast, 15% of the runners they studied had them, while nearly half had polyps in general. 'Consideration of refined screening strategies for this population is warranted,' the researchers wrote in their study. The team presented its results earlier this year at the annual conference of the American Society of Clinical Oncology. That means this study hasn't yet undergone the formal peer-review process. The authors are also quick to note their work isn't definitive proof that endurance running can cause colorectal cancer. Assuming this link is causative, there remains the burning question of why. As even weekend 5k joggers will know, running can occasionally trigger bouts of gastrointestinal distress (the namesake runner's diarrhea). These injuries are sometimes caused by temporarily restricted blood flow to the intestines that damages nearby cells. It's possible, the researchers speculate, that extreme runners who regularly experience this blood flow loss can develop the sort of chronic inflammation that makes cancer more likely to emerge. Being a Couch Potato Is Bad for Your Memory, Study Warns At this point, though, that's only one hypothesis for what may be happening here. The researchers say future studies should try to confirm their findings as well as untangle the causes and risk factors that could explain this potential higher risk. All that said, this research shouldn't scare anyone away from running or any other form of cardio. The many health benefits of regular physical activity—which importantly include a lower risk of at least eight different types of cancer—still far outweigh the risks for the average person.
Wall Street Journal
21 minutes ago
- Wall Street Journal
The Necessity of ObamaCare
In 'The Phantom Patients of ObamaCare' (Aug. 18), you write that because millions of Americans 'don't use' their subsidized insurance, they therefore 'don't need' it. Yet as we teach our students every year, this misunderstands the purpose of insurance. Not filing a claim doesn't mean you didn't need insurance. We've never had to use our oxygen masks during decades of flying, but that hardly means they're not essential. Prof. Amy Finkelstein
